<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762775</url>
  </required_header>
  <id_info>
    <org_study_id>33497</org_study_id>
    <secondary_id>08016</secondary_id>
    <nct_id>NCT00762775</nct_id>
  </id_info>
  <brief_title>The Interaction Between Calcium and Vitamin D Intake</brief_title>
  <acronym>PTH Modified</acronym>
  <official_title>The Interaction Between Calcium and Vitamin D Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study the relative importance of high calcium intake and vitamin D supplementation
      for calcium homeostasis, as determined by serum parathyroid hormone (PTH) and biochemical
      bone markers. We also intend to examine the interaction of vitamin D and calcium intake on
      calcium homeostasis. We hypothesize that optimal calcium supplementation and optimal vitamin
      D supplementation will lead to lower serum levels of PTH and markers of bone resorption
      compared with the placebo. We also theorize that when taken together, optimal calcium
      supplementation and optimal vitamin D intake will result in lower serum levels of PTH and
      bone markers compared with calcium or vitamin D taken alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The influence of calcium supplementation alone on serum PTH levels and bone markers in healthy adult women.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The interaction between calcium and vitamin D supplementation and their combined effect on serum PTH hormone levels and bone markers in healthy adult women.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium supplementation and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D supplementation and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium and Vitamin D supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium and vitamin D supplementation</intervention_name>
    <description>Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women aged 45 and above who have been menopausal at least 1 year (absence of
             menstrual period for a period of 12 months or more)

        Exclusion Criteria:

          -  Any chronic medical illness including uncontrolled diabetes mellitus, recent history
             of myocardial infarction, or heart failure, malignancy, uncontrolled hypertension,
             obesity (BMI&gt;35 kg/m2), history of anemia, leukemia, or other hematologic
             abnormalities, lupus, rheumatoid arthritis, or other rheumatologic disease, or kidney
             disease of any kind as determined by history and physical examination.

          -  Subjects with osteoporosis of the hip (total hip T-score equal or less than -2.5) or
             taking medications for osteoporosis such as bisphosphonates will be excluded.

          -  Pregnancy.

          -  Use of medication that influences bone metabolism (i.e. anticonvulsant medications,
             chronic use of steroids and high dose diuretics).

          -  Significant deviation from normal in medical history, physical examination, or
             laboratory tests as evaluated by the primary investigator.

          -  Patients with a history of hypercalciuria, hypercalcemia, nephrolithiasis, and active
             sarcoidosis will also be excluded.

          -  Participation in another investigational trial in the past 30 days prior to the
             screening evaluation.

          -  Unexplained weight loss of &gt;15% during the previous year or history of anorexia
             nervosa.

          -  Medications that interfere with vitamin D metabolism.

          -  Patients with a habitual dietary calcium intake that exceeds 800 mg/day.

          -  Smokers greater than 1 pack per day will be excluded.

          -  Patients reporting alcohol intake greater than 2 drinks daily.

          -  Serum 25-hydroxyvitamin D level &gt; 75 nmol/L.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. Aloia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Winthrop University Hospital</investigator_affiliation>
    <investigator_full_name>John F. Aloia, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bone resorption</keyword>
  <keyword>Calcium homeostasis</keyword>
  <keyword>Bone markers</keyword>
  <keyword>Calcium and Vitamin D supplementation</keyword>
  <keyword>Parathyroid hormone levels</keyword>
  <keyword>Interaction between calcium and vitamin D supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

